Labcorp consensus shapes Wall Street view, shares trade steadily on the NYSE
23.06.2026 - 13:32:58 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 13:31.
Labcorp (US50540R4092) sits in a tight range around the mid-250 dollar mark, with the healthcare diagnostics player trading on the NYSE under the ticker LH. Consensus data and technical models provide a cautious picture on the shares, according to several recent market screens.
What recent data say on Labcorp
MarketBeat shows Labcorp closing at 254.53 dollars on June 22, 2026, with a modest 0.50 percent decline in regular trading and near-flat moves after hours. The stockscan.io technical compilation places the current after-hours quote at 254.43 dollars, highlighting a narrow intraday spread and muted volatility in recent sessions.
Stockscan.io aggregates 17 technical indicators for Labcorp, classifying the setup as a strong sell signal, with 12 indicators pointing to selling, four neutral and only one suggesting a buy. These model-based signals contrast with the relatively stable price action, underlining the cautious tone among short-term trading algorithms rather than a pronounced directional move in the shares.
How analysts frame Labcorp’s outlook
Stockscan.io’s long-run scenario projects a 2026 average price of 289.28 dollars for Labcorp, with a high case of 348.29 dollars and a low-case estimate at 230.28 dollars. From the current reference around 254.43 dollars, this band implies a potential percentage change in the mid-teens, though the service characterizes the stock as a strong sell on a technical basis. This mix of longer-term upside models and near-term technical caution underscores the divided view among quantitative approaches.
On broader Wall Street screens, Labcorp frequently appears alongside large-cap healthcare peers such as Quest Diagnostics in diagnostics and UnitedHealth Group in managed care, sectors where earnings resilience has attracted institutional investors. While detailed rating distributions from major houses such as Goldman Sachs or JPMorgan were not newly refreshed in the latest day’s data, available consensus snapshots still point to expectations of mid-single-digit revenue growth and mid-teens earnings per share over the next few years, a profile consistent with mature healthcare services names.
All news and analysis on the Labcorp shares
Further reports, quotes and background on Labcorp, including price charts, consensus data and corporate disclosures, can be found on the dedicated topic page and the company’s investor relations site.
What Labcorp sells to generate cash flow
Labcorp’s core business is diagnostic testing for physicians, hospitals and patients, with large clinical laboratories processing blood, tissue and genetic samples across the United States. The company’s portfolio spans routine chemistry panels, oncology assays, women’s health screening and increasingly specialized genomic tests, positioning the group in the broader diagnostics and drug development services market. Through its central laboratories and specialty units, Labcorp also supports pharmaceutical trials with biomarker analysis and companion diagnostics, which can bring fee-based revenues tied to study volumes.
Where the Labcorp shares trade today
The Labcorp shares (US50540R4092) trade on the NYSE under ticker LH and recently closed at 254.53 dollars on June 22, 2026, with after-hours indications around 254.43 dollars.
Key data on the Labcorp shares
- Company: Laboratory Corporation of America Holdings
- ISIN: US50540R4092
- WKN: 888289
- Ticker: LH
- Trading venue: NYSE
- Price (as of 2026-06-22, 15:59): 254.53 USD
- Market cap: approximately 21.5 billion USD (as of 2026-06-22)
- Sector / industry: Health Care - Diagnostics & Research
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation or a solicitation to buy or sell any securities. All data are based on sources cited and may change over time; readers should verify key figures independently before making investment decisions.
